GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Stock Based Compensation

Defence Therapeutics (XCNQ:DTC) Stock Based Compensation : C$5.90 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Stock Based Compensation?

Defence Therapeutics's Stock Based Compensation for the three months ended in Dec. 2023 was C$5.84 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was C$5.90 Mil.


Defence Therapeutics Stock Based Compensation Historical Data

The historical data trend for Defence Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Stock Based Compensation Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Stock Based Compensation
0.18 0.61 0.37

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.23 0.06 - 5.84

Defence Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$5.90 Mil.


Defence Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director